Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on Lifestance Health Group yesterday and set a price target of $10.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Craig Hettenbach has given his Buy rating due to a combination of factors that indicate a positive outlook for LifeStance Health Group. The company is overcoming previous challenges, such as a payor rate reduction, and is showing signs of accelerated revenue growth. This is supported by an increase in clinician productivity and a significant rise in patient visits, which outpaces the growth in clinician numbers.
Additionally, LifeStance is implementing strategic initiatives like a cash incentive program and AI-assisted scheduling tools, which are enhancing operational efficiency and patient acquisition. The partnership with Calm is expected to expand referral sources, while the company’s healthy balance sheet provides opportunities for mergers and acquisitions, particularly in new geographic areas. These factors contribute to a robust growth trajectory and justify the optimistic rating.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFST in relation to earlier this year.